Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study)
NCT06238596 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38
Last updated 2025-10-03
Summary
This is a drug-free, single arm, single center, superiority, interventional study aimed at treatment feasibility.
The main aim of the current study is to assess feasibility of a tailored exercise program as measured by adherence to exercise program in metastatic PCa patients undergoing ADT.
Secondary aims are: to deepen the knowledge on other feasibility aspects (recruitment/retention), to monitor safety, to assess the effects in reducing the AEs of ADT (on loss of strength, loss of physical performance and fatigue, number of accidental falls and fractures), to monitor pain and the change in physical activity habits.
The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
At baseline a physiatrist will visit patients with bone metastasis and collect data on sites of bone metastasis, associated level of pain, and risk of pathological fractures. For all participants, the physiotherapist will assess muscle strength (Hand Grip Strength-HGS), physical performance (Short Physical Performance Battery-SPPB), level of fatigue (FACIT-F), and data collection on physical activity habits (International Physical Activity Questionnaire-IPAQ).
The enrollment will be closed after 1 year from the activation of the study or when the target of patients will be reached, whichever occurs firstly.
For each patient, data will be collected for 12 months. The duration of the study is expected to be around 2 years.
Follow-ups are scheduled at 12 weeks, 24 weeks and 12 months.
Conditions
- Metastatic Prostate Cancer (PCa) in ADT
- Rehabilitation
Interventions
- PROCEDURE
-
rehabilitation
The rehabilitation intervention will be led by a Physiotherapist and will include: a 12 weeks standardized multicomponent exercise (aerobic, resistance, balance and flexibility, and impact exercise if indicated), supervised by the physiotherapist, on an outpatient basis or in telerehabilitation. This program will be adapted to single patient needs. Every exercise session will last almost 60 minutes and patients will be supervised twice a week. One more exercise session per week will be self-managed by patients.
Sponsors & Collaborators
-
Azienda USL Reggio Emilia - IRCCS
lead OTHER_GOV
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-06
- Primary Completion
- 2025-03-03
- Completion
- 2026-05-31
Countries
- Italy
Study Locations
More Related Trials
-
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
NCT01715285 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
NCT06473259 ·Status: RECRUITING
-
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy
NCT03860961 ·Status: COMPLETED ·Phase: NA
-
Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy
NCT03070145 ·Status: COMPLETED ·Phase: NA
-
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
NCT01558427 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT01957436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients
NCT03526562 ·Status: COMPLETED ·Phase: NA
-
A Survivorship Care Plan and Embedded Navigation Tool
NCT03424837 ·Status: COMPLETED ·Phase: NA
-
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
NCT05156424 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
NCT06305832 ·Status: RECRUITING ·Phase: PHASE2
-
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation As a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial
NCT03655886 ·Status: COMPLETED ·Phase: PHASE2
-
Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)
NCT03129854 ·Status: RECRUITING ·Phase: NA
-
Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer
NCT00796458 ·Status: UNKNOWN ·Phase: PHASE3
-
Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
NCT01040624 ·Status: COMPLETED ·Phase: NA
-
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
NCT03436654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lifestyle Intervention in Patients With Metastatic Prostate Cancer
NCT05850182 ·Status: RECRUITING ·Phase: NA
-
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
NCT04523207 ·Status: COMPLETED ·Phase: PHASE2
-
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
NCT04181203 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
NCT02217566 ·Status: COMPLETED ·Phase: PHASE2
-
Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial
NCT03658486 ·Status: COMPLETED ·Phase: NA
-
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
NCT05781217 ·Status: RECRUITING ·Phase: PHASE3
-
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NCT06397703 ·Status: RECRUITING ·Phase: PHASE2
-
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
NCT03223597 ·Status: COMPLETED
-
Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
NCT02130947 ·Status: WITHDRAWN ·Phase: NA
-
Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy
NCT01410942 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2